Alcolase Raises €1.5M to Tackle Alcohol Intolerance with Enzyme Technology

Why It Matters

By enabling people with alcohol intolerance to consume drinks without adverse effects, Alcolase could unlock social and professional participation for hundreds of millions, creating a sizable niche in the global health‑and‑lifestyle market.

Key Takeaways

• Alcolase raised €1.5 M (~$1.6 M) from European and Asian investors
• Technology uses liposome‑encapsulated enzymes to break alcohol in the stomach
• Targets 540 million East Asians with ALDH2 deficiency causing alcohol intolerance
• First market launch planned for Singapore, followed by South Korea
• Funding will fund in‑vivo study, IP expansion, and partnership outreach

Pulse Analysis

Alcohol intolerance, driven largely by the ALDH2 genetic variant, affects an estimated 540 million people across East Asia. The condition not only triggers uncomfortable flushing and nausea but also limits participation in business dinners and networking events where drinking is customary. As societies place increasing value on inclusive social rituals, a solution that mitigates these physiological barriers could reshape cultural norms and expand consumer choice in a region where alcohol consumption is deeply embedded.

Alcolase’s approach leverages enzyme therapy protected by liposome encapsulation, allowing the active ingredient to survive stomach acidity and act directly on ingested ethanol. This delivery method differentiates the company from traditional over‑the‑counter remedies, which often rely on post‑drinking symptom relief rather than pre‑emptive breakdown. By targeting the metabolic step before alcohol enters the bloodstream, the technology promises a more efficient and potentially safer alternative, aligning with a broader biotech trend toward precision‑engineered nutraceuticals.

The recent €1.5 million funding round positions Alcolase to accelerate in‑vivo validation, solidify its patent portfolio, and initiate commercial pilots in Singapore—a market known for rapid adoption of health tech—before expanding into South Korea, where ALDH2 deficiency prevalence is high. Success could also open doors to a wider drug‑delivery platform, attracting further venture interest and strategic partnerships across the UK and Asia. Investors see the dual upside of addressing a massive, underserved health need while tapping into a culturally significant consumer segment, making Alcolase a compelling play in the emerging biotech‑consumer crossover space.